_1777370220974_847775619.png){kind=small}
Pfizer and Lilly invest in $1.3B AI drug firm
Chai Discovery, an AI drug discovery startup valued at $1.3 billion, is working with major pharmaceutical companies, including Pfizer and Eli Lilly, to develop new therapies using advanced antibody AI models. The company has signed significant partnerships and is in talks with additional firms to accelerate medicine development, benefiting from recent model improvements that increase the success rate of designing effective antibodies. Despite competition, Chai’s focus on providing technology access rather than developing its own drugs has positioned it as a leader in the rapidly growing AI pharmaceutical sector.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)